PMGC Holdings Inc. (ELAB) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Newport Beach, CA, アメリカ. 現CEOは Graydon Bensler.
ELAB を有する IPO日 2023-11-21, 2 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $8.13M.
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
